Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
281 hedge funds and large institutions have $6.22B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2019 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 87 increasing their positions, 105 reducing their positions, and 26 closing their positions.
96% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 26
37% more capital invested
Capital invested by funds: $4.54B → $6.22B (+$1.68B)
36% more call options, than puts
Call options by funds: $32.9M | Put options by funds: $24.1M
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
6% more funds holding
Funds holding: 264 → 281 (+17)
17% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$180M |
| 2 |
O
OrbiMed
New York
|
+$48.5M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$32.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$26.6M |
| 5 |
CGM
Capital Growth Management
Boston,
Massachusetts
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$71.6M |
| 2 |
DM
Deerfield Management
New York
|
-$52.7M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$51.9M |
| 4 |
RI
Redwood Investments
Boston,
Massachusetts
|
-$37.5M |
| 5 |
JP Morgan Chase
New York
|
-$36.1M |
HZNP Hedge Fund Activity: Q4 2019 in Review
281 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2019, worth a combined $6.22B — up 37% from $4.54B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new HZNP positions and 26 closed out — a net gain of 25 holders — while 87 added to existing stakes and 105 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $180M. The largest seller was HealthCor Management, exiting entirely with an estimated $71.6M sold.
- 281 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2019, up from 264 in Q3 2019.
- Funds reported $6.22B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2019, up 37% quarter-over-quarter.
- 51 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2019 and 26 closed out, a net change of +25 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2019 was Janus Henderson Group, an estimated $180M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2019 was HealthCor Management, an estimated $71.6M sold.
Based on aggregated 13F filings for Q4 2019.